GCTK Key Statistics, Chart & Performance
The current stock price of GCTK is 4.6 USD. In the past month the price decreased by -8.91%. In the past year, price decreased by -98.54%.
GCTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.09 | 217.71B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.34 | 205.55B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.69 | 142.95B | ||
| SYK | STRYKER CORP | 27.07 | 136.34B | ||
| BDX | BECTON DICKINSON AND CO | 13.64 | 56.15B | ||
| IDXX | IDEXX LABORATORIES INC | 55.68 | 56.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.67 | 50.21B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.29 | 38.24B | ||
| RMD | RESMED INC | 24.92 | 36.01B | ||
| DXCM | DEXCOM INC | 36.25 | 26.30B | ||
| PODD | INSULET CORP | 63.8 | 20.51B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.1 | 17.80B |
Related stock screener links
About GCTK
Company Profile
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Company Info
GLUCOTRACK INC
301 Rt 17 North, Suite 800
Rutherford NEW JERSEY US
Employees: 11
Phone: 197286757878
GLUCOTRACK INC / GCTK FAQ
What does GLUCOTRACK INC do?
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Can you provide the latest stock price for GLUCOTRACK INC?
The current stock price of GCTK is 4.6 USD. The price decreased by -2.95% in the last trading session.
Does GCTK stock pay dividends?
GCTK does not pay a dividend.
How is the ChartMill rating for GLUCOTRACK INC?
GCTK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does GLUCOTRACK INC belong to?
GLUCOTRACK INC (GCTK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the short interest for GCTK stock?
The outstanding short interest for GLUCOTRACK INC (GCTK) is 3.5% of its float.
GCTK Technical Analysis
GCTK Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GCTK. GCTK has a bad profitability rating. Also its financial health evaluation is rather negative.
GCTK Financial Highlights
Over the last trailing twelve months GCTK reported a non-GAAP Earnings per Share(EPS) of -1225.59. The EPS increased by 64.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -311.87% | ||
| ROE | -939.8% | ||
| Debt/Equity | 1.18 |